Vectura Group Stock

VEC

GB00BKM2MW97

Market Closed - London S.E. Other stock markets 11:35:22 2021-10-18 am EDT			5-day change	1st Jan Change
164.80 ^GBX	-.--%		-.--%	-

25-10-30	Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited	CI
24-09-16	Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million.	CI

Analysts' recommendations: Vectura Group

21-05-27	VECTURA : Panmure Downgrades Vectura Group To Hold From Buy, Raises PT	MT
21-01-22	VECTURA : Citigroup Downgrades Vectura To Neutral From Buy, Keeps PT	MT

More recommendations

News in other languages: Vectura Group

21-09-16	Résumé des principales informations économiques du jeudi 16 septembre
21-09-16	Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 16 septembre 2021
21-09-16	Philip Morris : offre inconditionnelle sur Vectura Group
21-09-16	Philip Morris International : confirme le rachat de Vectura
21-09-16	USA-Les valeurs à suivre à Wall Street (actualisé)

More news

Managers and Directors: Vectura Group

Manager	Title	Age	Since
Anthony Fitzpatrick CEO	Chief Executive Officer	-	-
Geraldine Venthoye CTO	Chief Tech/Sci/R&D Officer	-	2016-05-31
Robert J Zeitler SEC	Corporate Secretary	-	2025-06-29

Director	Title	Age	Since
Chad Williams BRD	Director/Board Member	53	2023-09-14
Charles Schumacher BRD	Director/Board Member	57	2025-06-29

More insiders

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Employees

Sector

More about the company

Market Cap	1B 878M 812M 750M 1.41B 96.5B 1.44B 9.68B 3.8B 47.25B 3.77B 3.69B 163B	P/E 2019	-27.3x	P/E 2020	6.2x
Enterprise Value	930M 813M 751M 694M 1.31B 89.35B 1.33B 8.96B 3.52B 43.75B 3.49B 3.42B 151B	EV / Sales 2019	2.8x	EV / Sales 2020	3.49x
Free-Float	-	Yield 2019 *	-	Yield 2020	-

25-10-30	Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited	CI
24-09-16	Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million.	CI
24-04-16	Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	CI
21-12-28	EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	CI
21-12-03	Philip Morris CEO does not need M&A to hit smoke free goals	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION"	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION	RE
21-12-02	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION"	RE

21-11-17	Vectura : wins Mediscience’s Best Communication Award Published17/11/2021 Read more	PU
21-09-14	Vectura : at Formulation and Delivery UK congress, London 21-22 September Published14/09/2021 Read more	PU
21-09-08	Norges Bank : - Form 8.3 - Vectura Group PLC	PR
21-09-01	Dimensional Fund Advisors Ltd. : Form 8.3 - VECTURA GROUP PLC - Ordinary Shares	AQ
21-08-24	Vectura : Our CDMO expertise in the spotlight Published24/08/2021 Read more	PU

5 years	149		176
10 years	59.1		180.88

Date	Insider	Type	Quantity	% Market Cap.
21-09-30	Paul Fry	Fiscal year	1,928,114	0.3160%
21-09-30	Paul Fry	Fiscal year	81,089	0.0133%
21-09-30	Paul Fry	Sell	119,429	0.0196%

Vectura Group Stock

Stocks

VEC

GB00BKM2MW97

Valuation: Vectura Group

Latest news : Vectura Group

Analysts' recommendations: Vectura Group

Press Releases: Vectura Group

News in other languages: Vectura Group

Course Extremes

Managers and Directors: Vectura Group

Latest insider transactions

Financials

Company Profile

	2019	2020
Net sales	178M 156M 144M 133M 251M 17.13B 255M 1.72B 674M 8.39B 670M 655M 28.88B	191M 167M 154M 142M 268M 18.31B 273M 1.84B 720M 8.96B 716M 700M 30.87B
Net income	-22.1M -19.31M -17.85M -16.49M -31.06M -2.12B -31.63M -213M -83.54M -1.04B -83.01M -81.18M -3.58B	122M 107M 98.88M 91.36M 172M 11.76B 175M 1.18B 463M 5.76B 460M 450M 19.82B
Net Debt	-66.5M -58.11M -53.72M -49.63M -93.47M -6.39B -95.16M -641M -251M -3.13B -250M -244M -10.77B	-74.4M -65.02M -60.1M -55.53M -105M -7.15B -106M -717M -281M -3.5B -279M -273M -12.05B